Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer

BACKGROUND: The emergence of HER2 antibody-drug conjugates provides new treatment decisions for breast cancer patients, especially those with HER2-low expression. In order to explore the biological characteristics of breast cancer with HER2-low expression, the HER2-low category in primary breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Jiuyan, Sun, Xuemei, Xu, Zihang, Cai, Lijing, Liu, Chang, Wu, Si, Liu, Yueping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992719/
https://www.ncbi.nlm.nih.gov/pubmed/36910643
http://dx.doi.org/10.3389/fonc.2023.1086480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992719/
https://www.ncbi.nlm.nih.gov/pubmed/36910643
http://dx.doi.org/10.3389/fonc.2023.1086480

Ejemplares similares